Drug intelligence / Profile preview

tegillidine

Development stage: Unknown
Lead developer: Hengrui Pharmaceutical
Modality: Small Molecules
Administration: Intravenous

Overview

Tegillidine is an analgesic agent currently under clinical investigation in China for the management of postoperative pain. It is being evaluated as a component of patient-controlled intravenous analgesia (PCIA) regimens, particularly following orthopedic procedures such as unilateral knee arthroplasty. In clinical trials, it has been compared to standard opioids like sufentanil to assess its analgesic efficacy, safety profile, and impact on rescue medication requirements. The drug is being developed and studied by institutions including The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University.

Other names: Tegillidine

Targets

MOR (Mu opioid receptor)

Beyond the preview

Go deeper on tegillidine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tegillidine.

Explore the full profile